Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Horizon Therapeutics Public Limited Company shares valued at $3,066,323 were sold by Pasternak Andy on Jan 17. At $113.03 per share, Pasternak Andy sold 27,129 shares. The insider’s holdings dropped to 56,338 shares worth approximately $5.63 million following the completion of this transaction.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Also, Cox Aaron sold 36,148 shares, netting a total of over 4,090,847 in proceeds. Following the sale of shares at $113.17 each, the insider now holds 277 shares.
Before that, SHERMAN JEFFREY W had sold 3,368 shares from its account. In a trade valued at $380,921, the EVP and Chief Medical Officer traded Horizon Therapeutics Public Limited Company shares for $113.10 each. Upon closing the transaction, the insider’s holdings decreased to 3,368 shares, worth approximately $3.61 million.
Analyzing HZNP Stock Performance
On Thursday, Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] rose 0.38% to $99.88. The stock’s lowest price that day was $99.24, but it reached a high of $100.23 in the same session. During the last five days, there has been a drop of approximately -1.72%. Over the course of the year, Horizon Therapeutics Public Limited Company shares have dropped approximately -12.23%. Shares of the company reached a 52-week high of $113.70 on 01/03/23 and a 52-week low of $90.56 on 05/16/23. A 50-day SMA is recorded $108.51, while a 200-day SMA reached $92.61. Nevertheless, trading volume fell to 1.15 million shares from 1.75 million shares the previous day.
Support And Resistance Levels for Horizon Therapeutics Public Limited Company (HZNP)
According to the 24-hour chart, there is a support level at 99.34, which, if violated, would cause prices to drop to 98.79. In the upper region, resistance lies at 100.33. The next price resistance is at 100.77. RSI (Relative Strength Index) is 33.61 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -4.79, which suggests the price will decrease in the coming days. Percent R is at 57.29%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Horizon Therapeutics Public Limited Company subject to short interest?
Stocks of Horizon Therapeutics Public Limited Company saw a sharp rise in short interest on May 14, 2023 jumping by 3.02 million shares to 6.95 million. Data from Yahoo Finance shows that the short interest on Apr 13, 2023 was 3.93 million shares. A jump of 43.45% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.53 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.53.
Which companies own the most shares of Horizon Therapeutics Public Limited Company (HZNP)?
According to The Vanguard Group, Inc. filings, the company currently owns 21,595,602 shares, which is about 9.45% of the total HZNP shares outstanding. The investor’s shares have appreciated by 542,885 from its previous 13-F filing of 21052717.0 shares. With the completion of the sale transaction, BlackRock Fund Advisors’s stake is now worth $1,214,779,157. Pentwater Capital Management LP acquire a 68.25% interest valued at $1.14 billion while Avoro Capital Advisor LLC 0 stake. In its current portfolio, JPMorgan Securities LLC holds 5,308,734 shares valued at $590.12 million.
In terms of Horizon Therapeutics Public Limited Company share price expectations, FactSet research, analysts set an average price target of $116.50 in the next 12 months, up nearly 17.09% from the previous closing price of $99.50. Analysts anticipate Horizon Therapeutics Public Limited Company stock to reach $116.50 by 2023, with the lowest price target being $116.50. In spite of this, 6 analysts ranked Horizon Therapeutics Public Limited Company stock as a Hold at the end of 2023.